Virios Therapeutics, Inc. (VIRI) — Financial statements
Income statement, balance sheet, and cash flow for Virios Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 22↓99.4% | 3,531↑204226.0% | 2↓78.6% | 8↓25.3% | 11 | |
| General & Administrative Expenses | 6↓99.9% | 8,696↑233745.3% | 4↓12.4% | 4↓12.4% | 5 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 6↓99.9% | 8,696↑233745.3% | 4↓12.4% | 4↓12.4% | 5 | |
| Other Expenses | 0.00 | 0.00 | 0.00↓100.0% | 0.07 | 0.00 | |
| Operating Expenses | 28↓99.8% | 12,227↑224380.1% | 5↓55.8% | 12↓21.3% | 16 | |
| Total Costs & Expenses | 0.00 | 0.00↓100.0% | 5↓55.8% | 12↓21.3% | 16 | |
| Operating Results | ||||||
| Operating Income | -27,968↓128.7% | -12,227↓224380.1% | -5↑55.8% | -12↑21.3% | -16 | |
| Depreciation & Amortization | 0.00 | 0.00↓100.0% | 5↓55.8% | 12↓21.3% | 16 | |
| EBITDA | -28↑99.8% | -12,227↓8102766.6% | 0.15↑101.2% | -12↑21.3% | -16 | |
| EBIT | 0.00↑100.0% | -12,258 | 0.00 | 0.00↑100.0% | -16 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↑100.0% | -92↓61193.1% | 0.15↑123.6% | 0.07 | 0.00 | |
| Interest Income | 0.00 | 0.00↓100.0% | 0.15↑123.6% | 0.07↑1089.6% | 0.01 | |
| Interest Expense | 0.10↓99.9% | 92 | 0.00 | 0.00↓100.0% | 0.01 | |
| Non-Operating Income | 0.00↓100.0% | 31 | 0.00 | 0.00↓100.0% | 0.31 | |
| Other Income / Expenses | -6,068↓4834.0% | -123↓81594.9% | 0.15↑123.6% | 0.07↑121.1% | -0.32 | |
| Income Before Tax | -34,036↓175.6% | -12,350↓233098.5% | -5↑56.8% | -12↑23.3% | -16 | |
| Income Tax Expense | -221↓44055.5% | 0.50 | 0.00↑100.0% | -0.07 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -36↑99.7% | -12,351↓233108.0% | -5↑56.5% | -12↑23.7% | -16 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -36↑99.7% | -12,864↓242796.4% | -5↑56.5% | -12↑23.7% | -16 | |
| Bottom-Line Net Income | -36↑99.7% | -12,864↓242796.4% | -5↑56.5% | -12↑23.7% | -16 | |
| EPS (Basic) | -7.13↑43.1% | -12.52↓4371.4% | -0.28↑74.5% | -1.10↑42.7% | -1.92 | |
| EPS (Diluted) | -7.13↑43.1% | -12.52↓4371.4% | -0.28↑74.5% | -1.10↑42.7% | -1.92 | |
| Weighted Average Shares | 5↓99.5% | 1,028↑5373.7% | 19↑69.6% | 11↑32.9% | 8 | |
| Weighted Average Diluted Shares | 5↓99.5% | 1,028↑5373.7% | 19↑69.6% | 11↑32.9% | 8 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.